Iovance Biotherapeutics (Nasdaq:IOVA) a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that it intends to offer and sell $125 million of its common stock, subject to market and other conditions, in an underwritten public offering.
As quoted in the press release:

Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund its planned clinical trials for our current product candidates, including planned Phase 2 clinical trial of LN-145 for the treatment of non-small cell lung cancer (NSCLC), in collaboration with MedImmune, as well as the NSCLC study in collaboration with the H.

Click here to read the full press release.